...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients
【24h】

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients

机译:多重皮滴数字PCR检测大肠癌患者血浆中循环DNA的KRAS突变

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Multiplex digital PCR (dPCR) enables noninvasive and sensitive detection of circulating tumor DNA with performance unachievable by current molecular-detection approaches. Furthermore, picodroplet dPCR facilitates simultaneous screening for multiple mutations from the same sample. METHODS: We investigated the utility of multiplex dPCR to screen for the 7 most common mutations in codons 12 and 13 of the KRAS (Kirsten rat sarcoma viral oncogene homolog) oncogene from plasma samples of patients with metastatic colorectal cancer. Fifty plasma samples were tested from patients forwhomthe primary tumor biopsy tissue DNA had been characterized by quantitative PCR. RESULTS: Tumor characterization revealed that 19 patient tumors had KRAS mutations. Multiplex dPCR analysis of the plasma DNA prepared from these samples identified 14 samples that matched the mutation identified in the tumor, 1 sample contained a different KRAS mutation, and 4 samples had no detectable mutation. Among the tumor samples that were wild type for KRAS, 2 KRAS mutations were identified in the corresponding plasma samples. Duplex dPCR (i.e., wild-type and single-mutation assay) was also used to analyze plasma samples from patients with KRASmutated tumors and 5 samples expected to contain the BRAF (v-raf murine sarcoma viral oncogene homolog B) V600E mutation. The results for the duplex analysis matched those for the multiplex analysis for KRASmutated samples and, owing to its higher sensitivity, enabled detection of 2 additional samples with low levels of KRAS-mutated DNA. All 5 samples with BRAF mutations were detected. CONCLUSIONS: This work demonstrates the clinical utility of multiplex dPCR to screen for multiple mutations simultaneously with a sensitivity sufficient to detect mutations in circulatingDNAobtained by noninvasive blood collection.
机译:背景:多重数字PCR(dPCR)能够以无创和灵敏的方式检测循环肿瘤DNA,其性能是当前分子检测方法无法实现的。此外,皮滴dPCR有助于从同一样品中同时筛选多个突变。方法:我们研究了多重dPCR在筛查转移性结直肠癌患者血浆中KRAS(Kirsten大鼠肉瘤病毒癌基因同源物)癌基因密码子12和13中最常见的7种突变的实用性。从患者中检测了五十份血浆样品,以通过定量PCR表征原发性肿瘤活检组织DNA。结果:肿瘤特征显示有19例患者肿瘤具有KRAS突变。从这些样品中制备的血浆DNA的多重dPCR分析确定了14个与肿瘤中鉴定的突变相匹配的样品,其中1个样品包含不同的KRAS突变,而4个样品没有可检测到的突变。在野生型KRAS肿瘤样品中,在相应的血浆样品中鉴定出2个KRAS突变。双链dPCR(即野生型和单突变分析)还用于分析患有KRAS突变肿瘤的患者的血浆样品和5个有望包含BRAF(v-raf鼠肉瘤病毒癌基因同源物B)V600E突变的样品。双重分析的结果与KRAS突变样品的多重分析结果相符,并且由于其更高的灵敏度,因此能够检测到另外两个具有低水平KRAS突变DNA的样品。检测到所有5个带有BRAF突变的样品。结论:这项工作证明了多重dPCR在同时筛选多个突变的临床实用性,其灵敏度足以检测无创采血获得的循环DNA中的突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号